Denali Therapeutics (DNLI) EPS (Basic): 2017-2024
Historic EPS (Basic) for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$0.68.
- Denali Therapeutics' EPS (Basic) rose 21.84% to -$0.68 in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.58, marking a year-over-year decrease of 145.71%. This contributed to the annual value of -$2.57 for FY2024, which is 142.45% down from last year.
- As of Q4 2024, Denali Therapeutics' EPS (Basic) stood at -$0.68, which was down 7.94% from -$0.63 recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' EPS (Basic) registered a high of $2.30 during Q4 2020, and its lowest value of -$0.87 during Q4 2023.
- For the 3-year period, Denali Therapeutics' EPS (Basic) averaged around -$0.52, with its median value being -$0.68 (2024).
- Its EPS (Basic) has fluctuated over the past 5 years, first spiked by 510.71% in 2020, then slumped by 144.03% in 2024.
- Quarterly analysis of 5 years shows Denali Therapeutics' EPS (Basic) stood at $2.30 in 2020, then plummeted by 126.96% to -$0.62 in 2021, then fell by 20.97% to -$0.75 in 2022, then declined by 16.00% to -$0.87 in 2023, then rose by 21.84% to -$0.68 in 2024.
- Its EPS (Basic) stands at -$0.68 for Q4 2024, versus -$0.63 for Q3 2024 and -$0.59 for Q2 2024.